Lifeward Ltd. (LFWD) Form 8-K — Aug 14, 2026
Lifeward Ltd. reported second quarter 2026 revenue of $6.6 million, up 16% year over year and its strongest quarterly performance since Q4 2024, driven by AlterG sales of $4.1 million (up 25%) and ReWalk exoskeleton sales of $2.5 million (up 13%). Operating loss narrowed 37% to $4.2 million, and CEO Mark Grant said he expects the revenue momentum to continue in the second half of 2026. GAAP net loss widened to $11.5 million, or $4.12 per share, from $6.6 million a year ago, primarily due to $6.9 million of non-cash fair-value charges on warrant and derivative liabilities, while non-GAAP net loss was $4.1 million.
Key figures
- Revenue
- 6623000
- Guidance
- Management expects revenue momentum to continue in the second half of 2026, backed by a strong sales pipeline
- Revenue Yoy
- 16
- Total Assets
- 35000000
- Cash Position
- 9448000
- Alter GSales Q2
- 4100000
- Gross Margin Q2
- 41%
- Opex Change Yoy
- -24% (prior year included $2.8M impairment charges)
- Re Walk Sales Q2
- 2500000
- Financing Raised
- 5600000
- Six Month Revenue
- 10546000
- Financing Capacity
- 11200000
- Reverse Split Ratio
- 1-for-12 (effected February 24, 2026)
- Proforma Cash Balance
- 11000000
- Weighted Avg Shares Q2
- 2796621
- Gross Margin Q2 Prior Year
- 44%
- Total Operating Expenses Q2
- 6861000
- Additional Tranche Milestone
- additional ~$5.6M available upon 150% increase in ReWalk sales or stock trading at $13.80+ for ten consecutive trading days
- Warrant Derivative Fair Value Charge Q2
- 6912000
Price after filing
Close on the filing date to close N calendar days later (from $7.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.